NO3081566T3 - - Google Patents

Info

Publication number
NO3081566T3
NO3081566T3 NO14869320A NO14869320A NO3081566T3 NO 3081566 T3 NO3081566 T3 NO 3081566T3 NO 14869320 A NO14869320 A NO 14869320A NO 14869320 A NO14869320 A NO 14869320A NO 3081566 T3 NO3081566 T3 NO 3081566T3
Authority
NO
Norway
Application number
NO14869320A
Other languages
Norwegian (no)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of NO3081566T3 publication Critical patent/NO3081566T3/no

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445Non condensed piperidines, e.g. piperocaine
    • A61K31/4523Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • A61K31/497Non-condensed pyrazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
NO14869320A 2013-12-13 2014-12-12 NO3081566T3 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2013258008 2013-12-13
PCT/JP2014/082943 WO2015087994A1 (ja) 2013-12-13 2014-12-12 5-ヒドロキシ-4-(トリフルオロメチル)ピラゾロピリジン誘導体

Publications (1)

Publication Number Publication Date
NO3081566T3 true NO3081566T3 (pl) 2018-08-04

Family

ID=53371291

Family Applications (1)

Application Number Title Priority Date Filing Date
NO14869320A NO3081566T3 (pl) 2013-12-13 2014-12-12

Country Status (29)

Country Link
US (1) US9796709B2 (pl)
EP (1) EP3081566B1 (pl)
JP (1) JP6465813B2 (pl)
KR (1) KR20160096612A (pl)
CN (1) CN105873928B (pl)
AU (1) AU2014362144B2 (pl)
BR (1) BR112016013500B8 (pl)
CA (1) CA2932707C (pl)
CY (1) CY1120256T1 (pl)
DK (1) DK3081566T3 (pl)
ES (1) ES2671377T3 (pl)
HR (1) HRP20180473T1 (pl)
HU (1) HUE038636T2 (pl)
IL (1) IL246006B (pl)
LT (1) LT3081566T (pl)
MX (1) MX368576B (pl)
MY (1) MY180338A (pl)
NO (1) NO3081566T3 (pl)
PH (1) PH12016501129A1 (pl)
PL (1) PL3081566T3 (pl)
PT (1) PT3081566T (pl)
RS (1) RS57088B1 (pl)
RU (1) RU2673810C1 (pl)
SG (1) SG11201604251UA (pl)
SI (1) SI3081566T1 (pl)
TR (1) TR201807696T4 (pl)
TW (1) TWI634120B (pl)
WO (1) WO2015087994A1 (pl)
ZA (1) ZA201603594B (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI713534B (zh) * 2015-06-11 2020-12-21 日商第一三共股份有限公司 5-羥基-4-(三氟甲基)吡唑并吡啶衍生物之結晶及其用途
CN106916143B (zh) * 2017-03-14 2019-09-27 哈尔滨医科大学 一种预防和治疗冠心病的药物及其应用
KR20200138202A (ko) 2018-03-30 2020-12-09 다이이찌 산쿄 가부시키가이샤 Lcat 결손증 치료약
CN108558847A (zh) * 2018-05-31 2018-09-21 马文军 一种酯类衍生物及其在防治心脑血管疾病中的应用
CN108530433A (zh) * 2018-05-31 2018-09-14 马文军 一种酯类衍生物及其在防治心脑血管疾病中的应用
CN108658830A (zh) * 2018-05-31 2018-10-16 马文军 一种酯类衍生物及其在防治心脑血管疾病中的应用
CN108774242B (zh) * 2018-08-22 2020-10-27 牡丹江医学院 一种防治冠心病的药物及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3130342B2 (ja) * 1991-10-04 2001-01-31 日産化学工業株式会社 動脈硬化性血管内膜肥厚抑制薬
KR20050069977A (ko) 2002-08-07 2005-07-05 미쯔비시 웰 파마 가부시키가이샤 디히드로피라졸로피리딘 화합물
US7135575B2 (en) * 2003-03-03 2006-11-14 Array Biopharma, Inc. P38 inhibitors and methods of use thereof
JP4833069B2 (ja) 2003-10-01 2011-12-07 ゼンション・リミテッド テトラヒドロ−ナフタレンおよび尿素誘導体
CA2787343C (en) * 2006-06-26 2016-08-02 Amgen Inc. Compositions comprising modified lcat and uses thereof
CA2689575A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
US8124807B2 (en) 2007-12-26 2012-02-28 Msd K.K. Sulfonyl-substituted 6-membered ring derivative
US20120041009A1 (en) 2009-05-18 2012-02-16 Sumitomo Chemical Company, Limited Pyrimidine compound and its use in pest control
BR112013000389A2 (pt) * 2010-07-09 2016-06-07 Daiichi Sankyo Co Ltd composto, composição farmacêutica, medicamento para inibir o cetp, medicamentos para aumentar a concentração o colesterol de hdl, e para diminuir a concentração do colesterol de ldl, uso do composto, e, método de tratamento ou profilaxia de uma doença
CA2809892C (en) * 2010-09-02 2019-05-28 Merck Patent Gmbh Pyrazolopyridinone derivatives as lpa receptor antagonists
EP2760864B1 (en) * 2011-09-27 2018-01-24 Dr. Reddy's Laboratories Ltd. 5-BENZYLAMINOMETHYL-6-AMINOPYRAZOLO[3,4-b]PYRIDINE DERIVATIVES AS CHOLESTERYL ESTER-TRANSFER PROTEIN (CETP) INHIBITORS USEFUL FOR THE TREATMENT OF ATHEROSCLEROSIS
JP6097225B2 (ja) * 2012-01-06 2017-03-15 第一三共株式会社 置換ピリジン化合物の酸付加塩
WO2013137371A1 (ja) * 2012-03-15 2013-09-19 興和株式会社 新規ピリミジン化合物及びそれらを含有する医薬
IN2014MN02512A (pl) * 2012-06-14 2015-07-17 Daiichi Sankyo Co Ltd

Also Published As

Publication number Publication date
ZA201603594B (en) 2019-04-24
US20160376267A1 (en) 2016-12-29
CN105873928A (zh) 2016-08-17
ES2671377T3 (es) 2018-06-06
EP3081566A4 (en) 2017-05-10
WO2015087994A1 (ja) 2015-06-18
CN105873928B (zh) 2018-01-23
PT3081566T (pt) 2018-05-08
MX368576B (es) 2019-10-08
EP3081566B1 (en) 2018-03-07
JPWO2015087994A1 (ja) 2017-03-16
US9796709B2 (en) 2017-10-24
IL246006B (en) 2019-09-26
RS57088B1 (sr) 2018-06-29
RU2673810C1 (ru) 2018-11-30
KR20160096612A (ko) 2016-08-16
PH12016501129B1 (en) 2016-07-18
LT3081566T (lt) 2018-05-25
EP3081566A1 (en) 2016-10-19
AU2014362144A2 (en) 2016-07-14
BR112016013500B1 (pt) 2020-06-16
PL3081566T3 (pl) 2018-07-31
HRP20180473T1 (hr) 2018-05-18
CA2932707A1 (en) 2015-06-18
AU2014362144A1 (en) 2016-06-16
TR201807696T4 (tr) 2018-06-21
SG11201604251UA (en) 2016-07-28
TW201609723A (zh) 2016-03-16
DK3081566T3 (en) 2018-06-06
TWI634120B (zh) 2018-09-01
JP6465813B2 (ja) 2019-02-06
MX2016007257A (es) 2016-09-07
PH12016501129A1 (en) 2016-07-18
MY180338A (en) 2020-11-28
HUE038636T2 (hu) 2018-12-28
CA2932707C (en) 2018-09-04
BR112016013500B8 (pt) 2020-07-14
IL246006A0 (en) 2016-08-02
AU2014362144B2 (en) 2018-05-10
SI3081566T1 (en) 2018-05-31
CY1120256T1 (el) 2019-07-10

Similar Documents

Publication Publication Date Title
AP2016009275A0 (pl)
BR112016014330A2 (pl)
BR112016008974A2 (pl)
BR112015007533A2 (pl)
BR112014017733A2 (pl)
BR112014017739A2 (pl)
BR112014018502A2 (pl)
BR112014019326A2 (pl)
BR112014018516A2 (pl)
BR112014017765A2 (pl)
BR112014017855A2 (pl)
BR112014021878A2 (pl)
BR112016011788A2 (pl)
BR122019026188A2 (pl)
BR112014018207A2 (pl)
BR112014017901A2 (pl)
BR112014019204A2 (pl)
BR112015015948A2 (pl)
BR112014017722A2 (pl)
BR112015016283A2 (pl)
BR112016012711A2 (pl)
BR112014018578A2 (pl)
BR112014018483A2 (pl)
BR112015015312A2 (pl)
BR112016004844A2 (pl)